Literature DB >> 16735170

Lymphatic filariasis: Treatment, control and elimination.

Eric A Ottesen1.   

Abstract

Lymphatic filariasis (LF) is a disease not just treatable or controllable; it is a disease that can be eliminated. Indeed, LF is currently the target of a major global initiative to do just that; a few visionaries of the past 50 years did hypothesize that LF elimination was feasible. However, for most of the scientific and global health communities, the elimination of such a broadly disseminated, mosquito-borne disease has seemed highly unlikely. During the past decade, however, both the treatment strategies and the control strategies for LF have undergone profound paradigm shifts-all because of a rapid increase in knowledge and understanding of LF that derived directly from a series of remarkable achievements by the scientific and medical research communities. As a result, a public health dimension with a focus on affected populations, now supplements the earlier, predominantly patient-oriented clinical approach to LF. The early uncertainties, then the essential steps leading to this change in outlook are outlined below, followed by descriptions of the new strategy for LF elimination, the Global Programme created to attain this goal and the successes achieved to date.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735170     DOI: 10.1016/S0065-308X(05)61010-X

Source DB:  PubMed          Journal:  Adv Parasitol        ISSN: 0065-308X            Impact factor:   3.870


  102 in total

1.  Preventive chemotherapy in human helminthiasis: theoretical and operational aspects.

Authors:  A-F Gabrielli; A Montresor; L Chitsulo; D Engels; L Savioli
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-10-29       Impact factor: 2.184

2.  Epidemiological assessment of continuing transmission of lymphatic filariasis in Samoa.

Authors:  H Joseph; F Maiava; T Naseri; U Silva; P Lammie; W Melrose
Journal:  Ann Trop Med Parasitol       Date:  2011-12

Review 3.  Control of neglected tropical diseases needs a long-term commitment.

Authors:  Yaobi Zhang; Chad MacArthur; Likezo Mubila; Shawn Baker
Journal:  BMC Med       Date:  2010-10-29       Impact factor: 8.775

4.  The role of Brugia malayi ATP-binding cassette (ABC) transporters in potentiating drug sensitivity.

Authors:  Jeffrey B Tompkins; Laurel E Stitt; Alana M Morrissette; Bernadette F Ardelli
Journal:  Parasitol Res       Date:  2011-04-15       Impact factor: 2.289

5.  Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells.

Authors:  Gregory M Nelson; Timothy P Padera; Igor Garkavtsev; Toshi Shioda; Rakesh K Jain
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

6.  Persistence of Brugia malayi DNA in vector and non-vector mosquitoes: implications for xenomonitoring and transmission monitoring of lymphatic filariasis.

Authors:  Peter Fischer; Sara M Erickson; Kerstin Fischer; Jeremy F Fuchs; Ramakrishna U Rao; Bruce M Christensen; Gary J Weil
Journal:  Am J Trop Med Hyg       Date:  2007-03       Impact factor: 2.345

7.  Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.

Authors:  Daniel J Tisch; Moses J Bockarie; Zachary Dimber; Benson Kiniboro; Nandao Tarongka; Fred E Hazlett; Will Kastens; Michael P Alpers; James W Kazura
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

Review 8.  The genome of Brugia malayi - all worms are not created equal.

Authors:  Alan L Scott; Elodie Ghedin
Journal:  Parasitol Int       Date:  2008-09-24       Impact factor: 2.230

Review 9.  Parasites and poverty: the case of schistosomiasis.

Authors:  Charles H King
Journal:  Acta Trop       Date:  2009-12-04       Impact factor: 3.112

Review 10.  Helminth infections: the great neglected tropical diseases.

Authors:  Peter J Hotez; Paul J Brindley; Jeffrey M Bethony; Charles H King; Edward J Pearce; Julie Jacobson
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.